Transgene

Transgene Share Buybacks

The Share Buybacks of Transgene (TNG.PA) as of Nov 18, 2026 is -158,000.00 EUR.

Share Buybacks

-158,000.00EUR

Last updated:

Share Buybacks of Transgene is 2024 -158,000.00 EUR. Share Buybacks of Transgene was 2023 0.00 EUR. It decreases by % lower compared to the previous year.

The Transgene Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2016
45.08 M EUR
Jan 1, 2017
13.27 M EUR
Jan 1, 2019
46.95 M EUR
Jan 1, 2020
0.00 EUR
Jan 1, 2021
33.34 M EUR
Jan 1, 2022
0.00 EUR
Jan 1, 2023
0.00 EUR
Jan 1, 2024
-158,000.00 EUR
The Transgene Share Buybacks history
YEARShare BuybacksYoY
-158,000.00EUR—
0.00EUR—
0.00EUR-100.00%
33.34 MEUR—
0.00EUR-100.00%
46.95 MEUR+253.73%
13.27 MEUR-70.56%
45.08 MEUR+9,350.73%
477,000.00EUR—
0.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Share Buybacks of Transgene is -158,000.00 EUR in 2024.

On Eulerpool you can find the complete historical development of Share Buybacks Transgene since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Transgene

All Key Metrics — Transgene